The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Maalox Plus 200 mg/175 mg/25 mg Oral Suspension



Opella Healthcare France SAS T/A SanofiPA23180/008/001

Main Information

Trade NameMaalox Plus 200 mg/175 mg/25 mg Oral Suspension
Active SubstancesAluminium hydroxide
Magnesium hydroxide
Simeticone
Dosage FormOral suspension
Licence HolderOpella Healthcare France SAS T/A Sanofi
Licence NumberPA23180/008/001

Group Information

ATC CodeA02AF Antacids with antiflatulents
A02AF02 ordinary salt combinations and antiflatulents

Status

Authorised/WithdrawnAuthorised
Licence Issued10/11/1975
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back